YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Aspen Pharmacare (APNHY) one of those stocks right now? A quick glance at the company's year-to-date…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Cardiol Therapeutics Inc. (CRDL) one of those stocks right now? By taking a look at the stock's year…
8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Pl…
TORONTO, May 14, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to an…
Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026. Reported positive Phase II ARCHER data showing CardiolRx™ significantly reduc…
The biotech sector has long offered investors high-risk, high-reward stocks. While large players are making headlines, the next wave of breakthroughs may come from companies flying well below Wall Street’s radar. These five under-the-radar…
For Immediate Release Chicago, IL – October 15, 2025 – Today, Zacks Equity Research discusses Akebia Therapeutics AKBA, Ironwood Pharmaceuticals IRWD, Pyxis Oncology PYXS, Cardiol Therapeutics CRDL and Plus Therapeutics PSTV. Industry: Dru…
The drug and biotech sector bounced back this month after struggling this year due to tariff and pricing fears and broader macro headwinds. The recovery was propelled by Pfizer’s landmark drug-pricing deal with Trump, wherein Pfizer was gr…
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan C…
[Stethoscope] adventtr/E+ via Getty Images * Cardiol Therapeutics (NASDAQ:CRDL [https://seekingalpha.com/symbol/CRDL]) shares up after it announced database lock for a mid-stage trial testing its lead asset, CardiolRx, on myocardial recove…
TORONTO - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL), a clinical-stage biotechnology company with a current market capitalization of $100.83 million, announced Tuesday the database lock for its Phase II ARCHER trial investigating C…
Oakville, Ontario--(Newsfile Corp. - June 29, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflam…
Oakville, Ontario--(Newsfile Corp. - June 27, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflam…
Initiated patient enrollment in a Phase II open-label clinical trial investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis - a debilitating heart disease associated with chest pain, shor…
Results Demonstrate Cannabidiol Improved Cardiac Function, Reduced its Inflammatory State, and Prevented the Development of Hypertrophy and Fibrosis in Heart Tissue Data Presented at The American College of Cardiology's 72nd Annual Scienti…
Vancouver, BC --News Direct-- Cardiol Therapeutics Cardiol Therapeutics CEO David Elsley shared news the company has hit a major milestone in that the first patient has been enrolled in a Phase II open-label pilot study of CardiolRx in pat…
The Cleveland Clinic Recruits First Participant in the Multi-center U.S. Study Oakville, Ontario--(Newsfile Corp. - January 17, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage lif…
The Cleveland Clinic and the Mayo Clinic Study Sites have been Initiated and are Eligible to Recruit Participants Initiation of Additional U.S. Cardiovascular Research Centers is Planned for Q1, 2023 Oakville, Ontario--(Newsfile Corp. - De…
Oakville, Ontario--(Newsfile Corp. - November 14, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-in…
Results Demonstrate Significant Reduction in Pericardial Effusion and Thickness and Significant Suppression of Key Inflammatory Markers IL-1β and IL-6 Data Presented at The American Heart Association Scientific Sessions 2022 Oakville, Onta…
Discontinues LANCER Trial due to Lack of Eligible Patients for Recruitment Cash Runway Now Extends into 2026 Oakville, Ontario--(Newsfile Corp. - October 25, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "C…
Data Presented at The Annual Scientific Meeting of the Heart Failure Society of America September 30th, 2022 Oakville, Ontario--(Newsfile Corp. - October 3, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Co…
Oakville, Ontario--(Newsfile Corp. - September 28, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-i…
RALEIGH, NC / ACCESSWIRE / September 27, 2022 / The 2nd Annual MicroCap Rodeo Conference is going on the road and will take place at the Swissotel in Chicago on October 12th - 13th, 2022, where 60+ SmallCap, MicroCap and NanoCap public com…
Multi-center, international, double-blind, randomized, placebo-controlled trial to enroll 100 patients Oakville, Ontario--(Newsfile Corp. - August 3, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company")…
We feel now is a pretty good time to analyse Cardiol Therapeutics Inc.'s (TSE:CRDL) business as it appears the company may be on the cusp of a considerable accomplishment. Cardiol Therapeutics Inc., a clinical-stage life sciences company,…
Oakville, Ontario--(Newsfile Corp. - June 29, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol…
Oakville, Ontario--(Newsfile Corp. - June 27, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol…
Oakville, Ontario--(Newsfile Corp. - June 9, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflamm…
Market Movers. Today's Top Stock Picks For New & Trending Opportunities VANCOUVER, BC / ACCESSWIRE / May 27, 2022 / Investors want insight. Welcome to the Market Movers Newsletter where we have created a snapshot of new and trending compan…
Emerging Growth Niche Companies in Environmental, Space, Technology, Biotechnology, and more in attendance MIAMI, May 24, 2022 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of…
MIAMI, May 24, 2022 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the…
Oakville, Ontario--(Newsfile Corp. - May 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-fibroti…
Third IND authorization for CardiolRx™ in cardiovascular disease Study to run in parallel with Company's multi-national Phase II acute myocarditis trial, expected to commence imminently CardiolRx™ is now eligible for orphan drug status in…
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with…
Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospitalized with COVID-19 Received authorization from the FDA to proceed with the Company's IND to com…